clinical trial · NCT05868382
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
ModernaTX, Inc.·phase2·completed·n = 270
InfluenzamRNA-1010mRNA-1010.4mRNA-1010.6
brief summary
The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.
started
May 15, 2023
primary completion
Dec 19, 2023
completion
Dec 19, 2023
last updated
Dec 20, 2024
official title
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol